Rahul Banerjee, MD, assistant professor, Clinical Research Division, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, discusses the challenges facing CAR T-cell therapy in multiple myeloma. Dr Banerjee notes that access to CAR T-cell therapy and the lengthy timeline for manufacturing may impact patient care.
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.
Teri Foy, PhD, Senior Vice President, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle site lead, and Mike Burgess, MD, PhD, Senior Vice President, Head of…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
Barry Paul, MD, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, discusses research related to idecabtagene vicleucel treatment for patients with newly diagnosed multiple myeloma and suboptimal responses…
Doris Hansen, MD, Moffitt Cancer Center, Tampa, Florida, discusses an analysis of pretreatment biomarkers associated with toxicity and durable response related to idecabtagene vicleucel therapy for patients with…
Rahul Banerjee, MD, assistant professor, Clinical Research Division, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, addresses the question of whether CAR T-cell therapy is a cure…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
